Elevation debuts with tumor-agnostic mAb in Phase II
Elevation Oncology’s lead program is in development for NRG1 fusion-driven solid tumors
Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners.
Elevation Oncology Inc. is developing therapies for cancers driven by rare mutations, starting with solid tumors with NRG1 fusions. Founder and CBO Shawn Leland told BioCentury the mutation is only present in about 0.2% of all solid tumors.
The start-up is collaborating with next-generation sequencing companies Ashion Analytics LLC, Strata Oncology Inc., Tempus Labs Inc.